{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-functional/prescribing-information/h2-receptor-antagonists/","result":{"pageContext":{"chapter":{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists","depth":2,"htmlHeader":"<!-- begin field e6e863d8-dd1b-4510-a56a-91b61dfb8dae --><h2>H2-receptor antagonists</h2><!-- end field e6e863d8-dd1b-4510-a56a-91b61dfb8dae -->","summary":"","htmlStringContent":"<!-- begin item f28152cf-e3ee-4362-af32-0471703b70d2 --><!-- end item f28152cf-e3ee-4362-af32-0471703b70d2 -->","topic":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272","topicId":"36754870-050c-4543-8dfe-bee25a1d10bb","topicName":"Dyspepsia - proven functional","slug":"dyspepsia-proven-functional","lastRevised":"Last revised in October 2018","chapters":[{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"63a6aa45-5022-5194-bebc-bd4481b831fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cdc4376-525a-5e58-8be2-dd0831642d02","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"257ffcf8-d6ac-58d1-b852-f9bb7329f249","slug":"changes","fullItemName":"Changes"},{"id":"d05055eb-ebd0-5056-b860-1ea85daeb311","slug":"update","fullItemName":"Update"}]},{"id":"b6f4608e-164d-578d-8142-8b175799683f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bf8575af-2f9b-5729-a628-5efb1ed0411d","slug":"goals","fullItemName":"Goals"},{"id":"761ef9c0-39a0-5dd7-9216-2dc7963b0a6a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9244dd4a-0551-5975-b909-6d728dfadcdd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9029a91f-3843-5e59-8544-cb7adfa2c457","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19b1713f-a518-57e7-a0c1-cdb48d0b4a0d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e265526e-adb9-5805-aedd-2e2bc77bb54c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"93b80ba3-9d73-5fc5-8b0e-7a57de8d6107","slug":"definition","fullItemName":"Definition"},{"id":"8f596c75-9a83-5d33-8b9a-4d18a9e24e2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a9f461a-38b9-56d1-8511-e41e822e0e8a","slug":"complications","fullItemName":"Complications"},{"id":"e7524b44-b1cf-50d9-806d-bd52695ec307","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a156deba-ce54-58e0-8984-13e20203cd70","fullItemName":"Management","slug":"management","subChapters":[{"id":"ff03390b-be65-558d-83cf-6808e0b84339","slug":"management-of-functional-dyspepsia","fullItemName":"Scenario: Management of functional dyspepsia"}]},{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"891aafa8-13c0-5175-b0ac-580bd4cbe1b8","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"a8c93904-08fc-57a4-b238-068ab96b5615","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"2d629b23-aa42-5503-980b-2c202de4c387","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4be75458-608e-5c04-9441-7001ced7fc6d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ad0185f-1607-5a33-9e94-892b09578c17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6489fce3-cac9-583f-a217-70ba5562de71","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e29927f4-a004-5126-a503-f1045ce72a28","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ca579371-2f3e-59ad-887e-7215f885a62a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"de65b79c-b356-54be-a611-9a871e60c85e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"43271e4f-f094-520d-bd20-f6582fc6ba97","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d9c7fc4f-2aae-51c4-b006-1303b60ef857","slug":"choice-of-h2-receptor-antagonist","fullItemName":"Choice of H2-receptor antagonist","depth":3,"htmlHeader":"<!-- begin field a23cad50-0b02-4e61-834a-1c1dc6632d30 --><h3>Choice of H2-receptor antagonist</h3><!-- end field a23cad50-0b02-4e61-834a-1c1dc6632d30 -->","summary":"","htmlStringContent":"<!-- begin item fd6c289d-df64-4d29-a807-42318abf55bd --><!-- begin field 03d4ca04-ff16-4b15-b219-1fee74e74150 --><ul><li>Table 1 shows the recommended doses of ranitidine, famotidine, and nizatidine histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) for the management of people with functional dyspepsia symptoms.</li></ul><p><strong>Table 1</strong><strong>. </strong>Recommended doses of H<sub>2</sub>RAs for the management of people with functional dyspepsia symptoms.</p><table><thead><tr><th colspan=\"1\"><p>H<sub>2</sub>RA</p></th><th colspan=\"1\"><p>Usual treatment dose</p></th><th colspan=\"1\"><p>Nocturnal dose</p></th></tr></thead><tbody><tr><td colspan=\"1\">Ranitidine</td><td colspan=\"1\">150 mg twice a day</td><td colspan=\"1\">300 mg at night</td></tr><tr><td colspan=\"1\">Famotidine</td><td colspan=\"1\">10 mg twice a day</td><td colspan=\"1\">—</td></tr><tr><td colspan=\"1\">Nizatidine</td><td colspan=\"1\">75 mg twice a day</td><td colspan=\"1\">—</td></tr><tr><td colspan=\"3\">Note: cimetidine is also licensed for the treatment of dyspepsia symptoms, however it is not recommended as there is a higher risk of drug interactions, due to inhibition of cytochrome P450 enzymes.</td></tr><tr><td colspan=\"3\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</td></tr></tbody></table><!-- end field 03d4ca04-ff16-4b15-b219-1fee74e74150 --><!-- end item fd6c289d-df64-4d29-a807-42318abf55bd -->","subChapters":[]},{"id":"eeec7d28-4cfc-5972-a211-eb0f3a36a24d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field c7d16a07-a13c-43d8-b3b3-a74a00e127d5 --><h3>Contraindications and cautions</h3><!-- end field c7d16a07-a13c-43d8-b3b3-a74a00e127d5 -->","summary":"","htmlStringContent":"<!-- begin item 5f360368-c58b-4001-8b17-a74a00e12704 --><!-- begin field e1ab91a3-53c8-4b34-88f3-a74a00e127d5 --><ul><li><strong>Histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) should not be prescribed to people:</strong><ul><li>With alarm symptoms before endoscopy, as H<sub>2</sub>RAs may mask the symptoms of upper gastrointestinal malignancy. If the person is already taking an H<sub>2</sub>RA and subsequently needs an endoscopy, the H<sub>2</sub>RA should be stopped at least 2 weeks before the procedure.</li></ul></li><li><strong>H<sub>2</sub>RAs should be prescribed with caution in people with renal impairment:</strong><ul><li>For ranitidine, if the estimated glomerular filtration rate (eGFR) is less than 50 mL/minute/1.73m<sup>2</sup>, prescribe half the normal daily dose.</li><li>For famotidine, if the eGFR is less than 50 mL/minute/1.73m<sup>2</sup>, prescribe the normal dose once every 36–48 hours, or half the normal daily dose.</li><li>For nizatidine, if the eGFR is 20–50 mL/minute/1.73 m<sup>2</sup>, prescribe half the normal daily dose; if the eGFR is less than 20 mL/minute/1.73 m<sup>2</sup>, prescribe one-quarter of the normal daily dose.</li></ul></li><li><strong>Nizatidine should be prescribed with caution for people with hepatic impairment.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field e1ab91a3-53c8-4b34-88f3-a74a00e127d5 --><!-- end item 5f360368-c58b-4001-8b17-a74a00e12704 -->","subChapters":[]},{"id":"be302ba9-7ff2-5ebe-adde-222f52b5135a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 36ef581b-e42d-49d5-9e58-a74a00e07b4b --><h3>Adverse effects</h3><!-- end field 36ef581b-e42d-49d5-9e58-a74a00e07b4b -->","summary":"","htmlStringContent":"<!-- begin item 965325a3-e5a5-4f4a-8e69-a74a00e07ae9 --><!-- begin field ddc3acaf-014d-46c9-b8f8-a74a00e07b4b --><ul><li>Adverse effects of histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) are uncommon and include diarrhoea, headache, dizziness, rash, and tiredness.</li><li>Rare or very rare adverse effects include hepatitis, cholestatic jaundice, bradycardia, depression, confusion, hallucinations, leucopenia, thrombocytopenia, and pancytopenia, arthralgia, and myalgia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field ddc3acaf-014d-46c9-b8f8-a74a00e07b4b --><!-- end item 965325a3-e5a5-4f4a-8e69-a74a00e07ae9 -->","subChapters":[]},{"id":"5bb4a610-81ba-5ed3-8680-7daee3070b2f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6e3826e0-c882-40a4-a80a-a74a00e08cb1 --><h3>Drug interactions</h3><!-- end field 6e3826e0-c882-40a4-a80a-a74a00e08cb1 -->","summary":"","htmlStringContent":"<!-- begin item 01869808-c520-420b-aba2-a74a00e08c88 --><!-- begin field 261e4524-7c06-4ed9-9b19-a74a00e08cb1 --><ul><li><strong>Possible drug interactions with histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) include:</strong><ul><li>Azole antifungals — because of decreased gastric acidity, the absorption of ketoconazole or itraconazole may be reduced if taken with an H<sub>2</sub>RA.</li><li>Protease inhibitors — atazanavir plasma levels are reduced by H<sub>2</sub>RAs. The manufacturer of atazanavir advises adjustment of the doses of both drugs when given with an H<sub>2</sub>RA. Seek specialist advice as needed.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field 261e4524-7c06-4ed9-9b19-a74a00e08cb1 --><!-- end item 01869808-c520-420b-aba2-a74a00e08c88 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}